Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03037515 · ClinicalTrials.gov registry record · Phase 4

Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

A Phase 4 study of Blood Loss, Surgical and Blood Loss Anemia, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 4
Development phase
83
Enrollment target
1
Study location

NCT03037515 is a Phase 4 study of Blood Loss, Surgical and Blood Loss Anemia that has completed, run by Henry Ford Health System. The registered enrollment target is 83 participants, below the 122-participant average among 6 other Blood Loss, Surgical trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03037515, a Phase 4 study of Blood Loss, Surgical and Blood Loss Anemia, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 4
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to compare the effectiveness of two different but well accepted routes of administration of tranexamic acid in order to reduce blood loss and need for transfusion in patients undergoing lumbar spine surgery. Specifically, this study seeks to identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion.

Interventions

  • DRUG Tranexamic Acid

Study Locations (1)

Michigan

  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2017-02-15
Est. Completion 2018-07-16
Phase Phase 4

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT03037515

The ClinicalTrials.gov registry entry for NCT03037515 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 6 other Blood Loss, Surgical trials with a reported enrollment target (32% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Blood Loss, Surgical appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic Acid is the first listed.

NCT03037515 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT03037515 about?

NCT03037515 is a clinical study titled "Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery". The purpose of this project is to compare the effectiveness of two different but well accepted routes of administration of tranexamic acid in order to reduce blood loss and need for transfusion in patients undergoing lumbar spine surgery. Specifically, this study seeks to identify if intravenous tra...

What is the current status of trial NCT03037515?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2017-02-15. Estimated completion is 2018-07-16.

What conditions does trial NCT03037515 study?

This clinical trial studies the following conditions: Blood Loss, Surgical, Blood Loss Anemia.

What interventions are being tested in trial NCT03037515?

The interventions under investigation include: Tranexamic Acid (DRUG).

Who is sponsoring clinical trial NCT03037515?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03037515 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blood Loss, Surgical

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.